Gallacher Capital Management LLC Sells 242 Shares of Novo Nordisk A/S (NYSE:NVO)

Gallacher Capital Management LLC decreased its position in Novo Nordisk A/S (NYSE:NVO) by 3.8% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 6,074 shares of the company’s stock after selling 242 shares during the period. Gallacher Capital Management LLC’s holdings in Novo Nordisk A/S were worth $628,000 at the end of the most recent quarter.

A number of other institutional investors have also bought and sold shares of NVO. Westside Investment Management Inc. raised its holdings in shares of Novo Nordisk A/S by 83.3% during the third quarter. Westside Investment Management Inc. now owns 1,428 shares of the company’s stock valued at $130,000 after purchasing an additional 649 shares during the period. Kranot Hishtalmut Le Morim Tichoniim Havera Menahelet LTD acquired a new position in Novo Nordisk A/S during the 3rd quarter worth approximately $2,408,000. Lazard Asset Management LLC boosted its holdings in Novo Nordisk A/S by 182.2% in the third quarter. Lazard Asset Management LLC now owns 1,494,214 shares of the company’s stock worth $135,883,000 after acquiring an additional 964,640 shares in the last quarter. CENTRAL TRUST Co grew its stake in Novo Nordisk A/S by 111.6% in the third quarter. CENTRAL TRUST Co now owns 6,004 shares of the company’s stock valued at $546,000 after acquiring an additional 3,166 shares during the period. Finally, Ieq Capital LLC raised its position in shares of Novo Nordisk A/S by 136.6% during the third quarter. Ieq Capital LLC now owns 27,474 shares of the company’s stock worth $2,498,000 after purchasing an additional 15,860 shares during the period. Institutional investors own 11.54% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research firms recently issued reports on NVO. BMO Capital Markets assumed coverage on shares of Novo Nordisk A/S in a research report on Friday, April 12th. They issued an “outperform” rating and a $163.00 price target for the company. UBS Group started coverage on shares of Novo Nordisk A/S in a report on Tuesday, January 16th. They set a “neutral” rating for the company. Cantor Fitzgerald restated an “overweight” rating and issued a $160.00 target price on shares of Novo Nordisk A/S in a report on Thursday, April 18th. Finally, Morgan Stanley initiated coverage on Novo Nordisk A/S in a research note on Tuesday, January 23rd. They set an “overweight” rating and a $120.00 price target for the company. Two analysts have rated the stock with a hold rating, six have issued a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $133.60.

Novo Nordisk A/S Stock Down 0.8 %

NVO stock traded down $0.97 during trading on Friday, reaching $123.05. The stock had a trading volume of 5,932,926 shares, compared to its average volume of 3,905,318. Novo Nordisk A/S has a one year low of $75.56 and a one year high of $138.28. The company’s 50 day moving average is $127.20 and its two-hundred day moving average is $113.10. The company has a quick ratio of 0.64, a current ratio of 0.82 and a debt-to-equity ratio of 0.19. The company has a market capitalization of $552.19 billion, a price-to-earnings ratio of 42.43, a P/E/G ratio of 2.06 and a beta of 0.43.

Novo Nordisk A/S (NYSE:NVO) last released its earnings results on Wednesday, January 31st. The company reported $0.71 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.66 by $0.05. The company had revenue of $9.51 billion during the quarter, compared to analyst estimates of $9.14 billion. Novo Nordisk A/S had a return on equity of 92.21% and a net margin of 36.56%. Equities research analysts forecast that Novo Nordisk A/S will post 3.32 EPS for the current year.

Novo Nordisk A/S Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.